Decentralized science (DeSci) is experiencing a significant surge in interest, highlighted by the explosive price action of Bio Protocol's BIO token. The token's value skyrocketed approximately 90% following a concrete catalyst: a $6.9 million funding round led by Maelstrom Fund. This capital injection supports the rollout of Bio V2, a full-stack, AI-native platform designed for onchain fundraising and featuring autonomous AI co-scientists called BioAgents.
The rally was specifically ignited by an AI-scientist angle, including a reported proposal for a peptide-based treatment targeting ADHD. The project's scientific team, in collaboration with @peptai_, developed OX2R-004, a compound targeting the orexin receptor (OX2R) which drives arousal and attention—a pathway with no currently approved activating drugs. This development electrified crypto-science communities, suggesting a tangible application of blockchain and AI in biotech.
Price data reveals a volatile but significant move, with BIO gaining over 93% in 24 hours and more than 120% over seven days, breaking out from a prolonged accumulation range between $0.015 and $0.018. The token now trades around $0.04061, though it faces firm resistance near $0.049. Analysts note the move originated from a low-liquidity range, making it fast and thin—a classic pattern for low-float DeSci tokens. The sustainability of the rally is now being tested, hinging on whether demand is tied to actual platform utility and results rather than transient narrative hype.
The event is also seen as part of a broader AI token momentum within crypto, suggesting the narrative extends beyond a single project. Furthermore, the surge underscores a growing trend in the DeSci sector, with infrastructure projects like LiquidChain aiming to build the necessary cross-chain layer to support future DeSci and DeFi applications, regardless of which individual tokens succeed.
